Osimertinib 80 MG Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Lung Cancer
Samsung Medical Center43 enrolled2 locationsNCT04591002
Recruiting
Phase 2
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
Shanghai Chest Hospital250 enrolled1 locationNCT07058519